Company: RGNT
Filing Date: 2025-10-24
Form Type: F-1/A
Source: 0001213900-25-101900
Chunk: 128

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-10-24
Form: F-1/A
Chunk 128
---
center'>79</div>

Patent applications (pending):

| Filing        
 Date          
 Dec. 14, 2016 
 Dec. 14, 2016 
 Dec. 14, 2016 |     | Application     
 Publication     
 No.             
 US 2022/0105240 
 EP 3389736      
 JP 2023-180906  |     | Title                                                        
 Organic solvent free compositions comprising protein-polymer 
 conjugates and uses thereof                                  
 Organic solvent free compositions comprising protein-polymer 
 conjugates and uses thereof                                  
 Organic solvent free compositions comprising protein-polymer 
 conjugates and uses thereof                                  |     | Country 
 USA     
 Europe  
 Japan   |     | Product 
 GelrinC 
 GelrinC 
 GelrinC |     | Type           
 of             
 application    
 Utility Patent 
 Utility Patent 
 Utility Patent |     | Projected     
 expiry date   
 Dec. 14, 2036 
 Dec. 14, 2036 
 Dec. 14, 2036 |
|:--------------|:----|:----------------|:----|:-------------------------------------------------------------|:----|:--------|:----|:--------|:----|:---------------|:----|:--------------|
| Dec. 14, 2016 |     | CA 3006695      |     | Organic solvent free compositions comprising protein-polymer 
 conjugates and uses thereof                                  |     | Canada  |     | GelrinC |     | Utility Patent |     | Dec. 14, 2036 |

| 1 | Nominal expiration date                                                                                           
 based on earliest effective filing date. Not including any possible future patent term extensions or adjustments. |

| 2 | As part                                                                                                                                     
 of our intellectual property strategy, we routinely file new patent applications aimed at protecting improvements and innovations           
 across our product candidates and platforms. We actively manage our patent portfolio to ensure continuity of coverage, including            
 filing newer, more targeted patent applications as older patents near expiration. We believe that the anticipated expiration of three       
 U.S. patents related to our Gelrin technology—each scheduled to expire in the near term—does not create a material gap                      
 in our intellectual property coverage or competitive position, due to newer, complementary patents and our ongoing innovation. Accordingly, 
 we do not rely on these expiring patents with respect to our current product candidates.                                                    |

Data Agreement with TiGenix

We entered into a data agreement with TiGenix dated July 20, 2015